文献速递其他结缔组织病

低剂量利妥昔单抗对难治性特发性炎性肌病有效

Low-dose rituximab is efficacious in refractory idiopathic inflammatory myopathies.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

这项基于注册表的观察性研究纳入2018至2021年间接受利妥昔单抗治疗的42例难治性特发性炎性肌病患者,评估6个月和12个月随访时的疗效。结果显示IMACS核心指标和激素用量均较基线改善,且500 mg×2次方案与1 g×2次方案在6个月和12个月时疗效相当。

要点

  • 42例难治性特发性炎性肌病患者接受利妥昔单抗后,6个月和12个月时MMT-8、PGA、PtGA及激素中位剂量均较基线改善(P<0.01)。
  • 6个月和12个月总改善评分平均分别提高44.5和48.7。
  • 500 mg×2次与1 g×2次两种剂量方案在6个月和12个月时MMT-8、PGA、PtGA较基线的变化相当。

核心结论

  • 在这项基于注册表的研究中,利妥昔单抗改善了特发性炎性肌病患者的IMACS核心指标,并在6个月和12个月时具有激素节约疗效。
  • 利妥昔单抗以500 mg×2次作为诱导方案,在6个月和12个月随访时与1 g×2次方案疗效相当。

研究设计与样本

  • 基于注册表的观察性研究,纳入2018年至2021年间接受利妥昔单抗治疗的特发性炎性肌病患者。
  • 共42例患者(女性:男性=29:13),平均(标准差)年龄39.5(11.5)岁。
  • 总改善评分按国际肌炎评估与临床研究组(IMACS)标准,由核心指标集在基线、6个月和12个月随访时计算。

主要发现

  • 多数患者因难治性肌炎接受利妥昔单抗,中位(四分位距)病程为8(4,18)个月。
  • 28例接受利妥昔单抗1 g×2次剂量,14例接受500 mg×2次剂量、间隔15天。
  • 利妥昔单抗治疗后6个月和12个月,MMT-8评分、PGA、PtGA及激素中位剂量较基线改善(P<0.01)。
  • 6个月和12个月总改善评分平均(标准差)分别提高44.5(16)和48.7(19.2)。
  • 两种利妥昔单抗剂量方案在6个月和12个月时MMT-8、PGA、PtGA较基线的变化相当。

关键数值与推荐

  • 总改善评分按IMACS标准由核心指标集计算。
  • 6个月总改善评分平均(标准差)提高44.5(16),12个月提高48.7(19.2)。
  • MMT-8、PGA、PtGA及激素中位剂量在6个月和12个月较基线改善,P<0.01。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Rituximab (RTX) use early in the course of refractory idiopathic inflammatory myopathy (IIM) is not well studied. This study sought to determine the short-term efficacy of RTX in a registry-based cohort of refractory IIM. METHODS: Registry-based observational data about IIM patients receiving RTX between 2018 and 2021 were included. Total improvement score was calculated from the core set measures as per International Myositis Assessment and Clinical Studies group (IMACS) at baseline, 6 months and 12 months of follow-up. RESULTS: Forty-two patients (F:M, 29:13), with a mean (s.d.) age of 39.5 (11.5) years were studied. Majority of patients received RTX for refractory myositis, after a median (interquartile range) duration of 8 (4,18) months. Twenty-eight received RTX at a dosage of 1 g × two doses, while 14 received 500 mg × two doses with an interval of 15 days. At 6 months and 12 months post-RTX, the improvement was recorded in manual muscle testing (MMT-8) scores, physician global assessment (PGA), patient global assessment (PtGA) and median steroid dosage as compared with the baseline (P < 0.01 for all). A mean (s.d.) improvement of 44.5 (16) and 48.7 (19.2) in total improvement score was recorded at 6 and 12 months, respectively. The change in MMT-8, PGA and PtGA scores from baseline between the two dosage regimens of RTX were comparable at 6 and 12 months. Severe lower respiratory tract infections requiring hospitalization occurred in three patients of the cohort. CONCLUSION: RTX improved IMACS core set measures and had steroid sparing efficacy at 6 and 12 months in patients with IIM in this registry-based study. Rituximab as an induction regimen of two doses of 500 mg can be as efficacious as 1 g at 6 months and 12 months of follow-up.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Janardana R, Amin SN, Rajasekhar L, et al. Low-dose rituximab is efficacious in refractory idiopathic inflammatory myopathies. Rheumatology (Oxford). 2023. PMID: 35946502. doi:10.1093/rheumatology/keac438

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。